Visual Acuity
Conditions
Brief summary
This is a single-masked, dispensing clinical trial. A total of approximately 48 myopic and 32 hyperopic eligible subjects will be targeted to complete the study. Subjects will be fit in the study lens, optimized if required and worn for approximately 2 weeks. Subjects will then have a washout period of approximately 1 week and be refit in the lenses and be dispensed for an additional 2 weeks of wear.
Interventions
JJVC Marketed Contact Lens
Sponsors
Johnson & Johnson Vision Care, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Potential subjects must satisfy all the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. The subject must be between 40 and 70 years of age at the time of screening. 4. Subjects must own a wearable pair of spectacles if required for their distance vision. 5. The subject must be an adapted monovision soft contact lens wearer in both eyes (i.e., worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration). 6. The subject's distance spherical equivalent refraction must be in the range of +3.50 D to -4.00 D in each eye. 7. The subject's refractive cylinder must be ≤1.00 D in each eye. 8. The subject's ADD power must be in the range of +0.75 D to +2.50 D. 9. The subject must have best corrected distance visual acuity of 20/20-3 or better in each eye.
Exclusion criteria
* Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. Currently Pregnant or lactating. 2. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g., hepatitis, tuberculosis). 3. Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), systemic steroids. 4. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, dacryocystorhinostomy, etc.). 5. Use of any ocular medication, with the exception of rewetting drops. 6. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment. 7. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician). 8. Any known hypersensitivity or allergic reaction to OPTI-FREE® Puremoist® care cleaning solution, non-preserved rewetting drop solution or sodium fluorescein. 9. History of herpetic keratitis. 10. Entropion, ectropion, chalazia, glaucoma, history of recurrent corneal erosions. 11. A history of amblyopia, strabismus or binocular vision abnormality. 12. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear. 13. Any ocular infection or inflammation. 14. Any ocular abnormality that may interfere with contact lens wear. 15. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vision Scores | 2-Week Follow-up | Vision Scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. |
| Visual Performance (logMAR) | 2-Week Follow-up | Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be etween 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64 cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2). Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle | Up to 2-Week Follow-up | Vision Scores wwere assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. |
Countries
United States
Participant flow
Recruitment details
A total of 91 subjects were enrolled in this study. Of those enrolled, 86 subjects were dispensed a least one study lens while 5 subjects failed to meet all eligibility criteria. Of those dispensed, 79 subjects completed the study, while 7 were discontinued.
Participants by arm
| Arm | Count |
|---|---|
| Test Subjects received the Test lens throughout the study. Subjects wore the Test lens twice for a period of approximately 2 weeks each. | 86 |
| Total | 86 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| First Wearing Cycle | Lens Discomfort | 2 |
| First Wearing Cycle | Protocol Violation | 1 |
| First Wearing Cycle | Time required to complete last two study visits exceeds study deadline | 1 |
| First Wearing Cycle | Unsatisfactory Visual Response due to Test Article | 1 |
| First Wearing Cycle | Withdrawal by Subject | 1 |
| Second Wearing Cycle | Adverse Event | 1 |
Baseline characteristics
| Characteristic | Test |
|---|---|
| Age, Continuous | 54.8 Years STANDARD_DEVIATION 6.24 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 5 Participants |
| Race (NIH/OMB) Black or African American | 13 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 67 Participants |
| Region of Enrollment United States | 86 Participants |
| Sex: Female, Male Female | 69 Participants |
| Sex: Female, Male Male | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 86 |
| other Total, other adverse events | 0 / 86 |
| serious Total, serious adverse events | 1 / 86 |
Outcome results
Primary
Vision Scores
Vision Scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
Time frame: 2-Week Follow-up
Population: Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Test (First Wearing Cycle) | Vision Scores | 59.38 Units on a Scale | Standard Deviation 19.7 |
| Test (Second Wearing Cycle) | Vision Scores | 56.19 Units on a Scale | Standard Deviation 23.387 |
95% CI: [54.6, 64]Linear Mixed Model
Primary
Visual Performance (logMAR)
Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be etween 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64 cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2). Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.
Time frame: 2-Week Follow-up
Population: Subjects that completed all study visits without a major prtocol deviation impacting a primary endpoint
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Test (First Wearing Cycle) | Visual Performance (logMAR) | Distance (4 Meter) | -0.08 logMAR | Standard Deviation 0.097 |
| Test (First Wearing Cycle) | Visual Performance (logMAR) | Intermediate (64 CM) | -0.02 logMAR | Standard Deviation 0.096 |
| Test (First Wearing Cycle) | Visual Performance (logMAR) | Near (40 CM) | 0.04 logMAR | Standard Deviation 0.085 |
| Test (Second Wearing Cycle) | Visual Performance (logMAR) | Distance (4 Meter) | -0.08 logMAR | Standard Deviation 0.1 |
| Test (Second Wearing Cycle) | Visual Performance (logMAR) | Intermediate (64 CM) | -0.03 logMAR | Standard Deviation 0.095 |
| Test (Second Wearing Cycle) | Visual Performance (logMAR) | Near (40 CM) | 0.02 logMAR | Standard Deviation 0.081 |
95% CI: [-0.124, -0.044]Linear Mixed Model
Comparison: Intermediate (64 CM)95% CI: [-0.068, 0.012]Linear Mixed Model
Comparison: Near (40 CM)95% CI: [-0.003, 0.077]Linear Mixed Model
Secondary
CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle
Vision Scores wwere assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
Time frame: Up to 2-Week Follow-up
Population: Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Test (First Wearing Cycle) | CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle | 59.38 Units on a Scale | Standard Deviation 19.7 |
| Test (Second Wearing Cycle) | CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle | 56.19 Units on a Scale | Standard Deviation 23.387 |
95% CI: [-8.1, -0.1]Linear Mixed Model